By vgreene, 19 May, 2020 Proposed mechanism: inhibits kinases which may play role in viral entry, replication, and egress; prevents viral/cell fusion via lysosomal alkalinization; anti-inflammatory activity in animal models attenuates acute lung injury
By vgreene, 19 May, 2020 Clinical Efficacy of Hydroxychloroquine in Patients With COVID-19 Pneumonia Who Require Oxygen: Observational Comparative Study Using Routine Care Data; full-text BMJ article
By vgreene, 19 May, 2020 Hydroxychloroquine in Patients With Mainly Mild to Moderate Coronavirus Disease 2019: An Open-Label, Randomised, Controlled Trial
By vgreene, 19 May, 2020 Study considerations: randomized but open-label; most pts received other potential antivirals; delayed tx initiation from sx onset; almost all pts had mild-moderate dz; higher HCQ dose and duration than other studies
By vgreene, 19 May, 2020 No difference in primary endpoint of viral clearance (85% HCQ vs 81% SOC) or secondary endpoint of sx improvement rate (60% HCQ vs 67% SOC); higher rate of ADRs in HCQ group (30% vs 9%)
By vgreene, 19 May, 2020 Multicenter, open-label, RCT; 150 hospitalized pts (mean age 46y; 99% mild or moderate dz; 63% received other antivirals) randomized 1:1 to SOC or SOC plus HCQ 1,200 daily x3 days, then 800 mg daily for total of 2-3wk based on dz severity; 17 days mean ti
By vgreene, 19 May, 2020 Clinical and Virologic Characteristics of the First 12 Patients With Coronavirus Disease 2019 (COVID-19) in the United States; full-text Nat Med article